Contracting Office Address
Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6068, Rockville, MD 20852, UNITED STATES.

Description
The National Cancer Institute (NCI), Center Division of Cancer Epidemiology and Genetics (DCEG), Occupational and Environmental Epidemiology Branch (OEEB), plans to procure on a sole source basis services for review of etiologic factors for prostate cancer progression in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial with:

Georgetown University
Office of Sponsored Research
3300 Whitehaven Street NW
Harris Building
Suite 1100
Washington, DC 20007

Henry Ford Health System
One Ford Place
Detroit, MI 48209

The University of Pittsburgh
4C, UPMC Cancer Pavilion
5150 Centre Avenue
Pittsburgh, PA 15232

The Regents of the University of Colorado
PLCO Cancer Screening Trial,
University of Colorado Denver,
13001 E 17th Place, Room N6203L,
Aurora, CO 80045

Marshfield Clinic
Marshfield Clinic Research Foundation
1R3
1000 N Oak Avenue
Marshfield, WI 54449

This acquisition will be processed in accordance with the simplified acquisition procedures as authorized by FAR Part 13.106-1 (b)(1). The North American Industry Classification System code is 541990 and the business size standard is $7 Million.

NCI expects to make multiple sole source firm fixed price awards as a result of this solicitation.

Period of performance shall be for twelve months from date of award with one twelve month option period.

Contractor Requirements:

Contractor must be one of 10 screening centers participating in the PLCO Trial. Each of these centers has obtained IRB approval to contact and actively follow PLCO participants in their area over the course of the PLCO Trial.

The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, sponsored by the National Cancer Institute, is a multicenter randomized trial that is evaluating the effectiveness of prostate, lung, colorectal, and ovarian cancer screening modalities on disease-specific mortality. To date, over 7500 men have been diagnosed with early stage prostate cancer while participating in the PLCO trial. On average, between 15-35% of men with early stage disease will experience a biochemical recurrence (elevation in PSA) after receiving initial treatment for their prostate cancer. The additional data collection requested will develop a PLCO resource that can facilitate the identification of the most relevant etiologic factors associated with prostate cancer recurrence and progression.

The purpose of these procurements is to obtain additional clinical and treatment information from men diagnosed with clinically localized prostate cancer in PLCO. Information will be collected by telephone interview with the male subject, or a proxy if necessary, and any self-reported recurrence, metastasis, or secondary treatment will be validated with medical records. Each institute has the following required participants:

Henry Ford Health System - 332 men
The Regents of the University of Colorado - 554 men
Georgetown University - 409 men
University of Pittsburgh - 637 men
Marshfield Clinic - 757 men

During the option year the contractor shall request tissue samples from the contractor for those men who had a prostatectomy, have signed the necessary PLCO consent forms, have not already had their tissue collected by PLCO previously, and reported recurrence, metastasis, or any secondary treatment in the telephone interview. All samples will be sent to a lab designated by NCI. Each institute will provide the following number of tissue samples:

Henry Ford Health System - 25 samples
The Regents of the University of Colorado - 30 samples
Georgetown University - 30 samples
University of Pittsburgh - 38 samples
Marshfield Clinic - 30 samples

This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on September 6, 2010. No electronic capability statements will be accepted (i.e. email or fax). An original and one copy must be sent to the NCI Office of Acquisitions at the address stated above. All questions must be in writing and may be faxed (301) 402-4513 or emailed to Terry Galloway, Contract Specialist at [email protected]. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-100193-TG on all correspondence.

Bid Protests Not Available